1. OP24 Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn's disease. (25th January 2019) Authors: Fumery, M; Peyrin-biroulet, L; Nancey, S; Altwegg, R; Veyrard, P; Bouguen, G; Viennot, S; Poullenot, F; Filippi, J; Buisson, A; Bozon, A; Gilletta, C; Brazier, F; Pouillon, L; Flourié, B; Boivineau, L; Siproudhis, L; Laharie, D; Roblin, X; Treton, X Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P369 Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre study. (16th January 2018) Authors: Streichenberger, A; Pariente, B; Bozon, A; Arab, N; Amiot, A; Vuitton, L; Tilmant, M; Nachury, M; Altwegg, R; Delasalle, T; Gagnière, C; Grégoire, B; Fumery, M; Wils, P; Pineton de Chambrun, G; Hébuterne, X; Pereira, B; Bommelaer, G; Buisson, A Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S291 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study. (21st January 2022) Authors: Bozon, A; Serrero, M; Caillo, L; Gilletta, C; Benezech, A; Nancey, S; Combes, R; Danan, G; Akouete, S; Pages, L; Bourgaux, J F; Boivineau, L; Meszaros, M; Altwegg, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i537 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗